Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents.
about
High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell linesData mining using the Catalogue of Somatic Mutations in Cancer BioMartPreclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and ValidationCancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer MedicineTumor-Derived Cell Lines as Molecular Models of Cancer PharmacogenomicsTargeting melanoma by small molecules: challenges aheadStructure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive reviewAssay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid CulturesHigh throughput ratio imaging to profile caspase activity: potential application in multiparameter high content apoptosis analysis and drug screeningSystems biology approaches for advancing the discovery of effective drug combinationsDetection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.Choosing the right cell line for renal cell cancer researchUsing Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer TherapyLoss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cellsSystematic analysis of cell cycle effects of common drugs leads to the discovery of a suppressive interaction between gemfibrozil and fluoxetineAn antitubulin agent BCFMT inhibits proliferation of cancer cells and induces cell death by inhibiting microtubule dynamicsMachine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical propertiesA versatile, bar-coded nuclear marker/reporter for live cell fluorescent and multiplexed high content imagingProof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myelomaComparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical useIntegrated analysis of transcriptome in cancer patient-derived xenograftsHER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1BA Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer CompoundsA 3D-microtissue-based phenotypic screening of radiation resistant tumor cells with synchronized chemotherapeutic treatmentHarnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancerMicroengineering methods for cell-based microarrays and high-throughput drug-screening applicationsAMF-26, a novel inhibitor of the Golgi system, targeting ADP-ribosylation factor 1 (Arf1) with potential for cancer therapy.In vitro optimization of EtNBS-PDT against hypoxic tumor environments with a tiered, high-content, 3D model optical screening platform.Personalized chemotherapy profiling using cancer cell lines from selectable miceThe mutational landscape of chromatin regulatory factors across 4,623 tumor samples.Novel amphiphilic cationic porphyrin and its Ag(II) complex as potential anticancer agents.StickWRLD as an Interactive Visual Pre-Filter for Canceromics-Centric Expression Quantitative Trait Locus Data.Ascites-derived pancreatic ductal adenocarcinoma primary cell cultures as a platform for personalised medicine.EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR.Preclinical efficacy testing for stomach and liver cancers.Multicellular tumor spheroids as a model for assessing delivery of oligonucleotides in three dimensionsIn vitro clinical trials: the future of cell-based profiling.
P2860
Q23058134-4F29428C-FAFC-47BC-A83E-325BBE4A0329Q24604621-8BBA3915-3EB5-4012-ACB3-9B4C47296DC4Q26784048-2D76804E-7E72-45B9-918B-D6C599CA21F7Q26800337-ED7E9864-917C-4C29-8A15-C6753A15941FQ26801410-EAE7DF6E-0FD1-43B4-B7A4-3C5CFF7FD128Q26824642-6172F8C2-0BA8-4874-AE4A-EECB75EC78EBQ27008867-80D4A625-C965-4DD0-957C-EB506A7C9DC4Q27324252-BE414A31-C4B7-4028-8132-434358B096AAQ27339765-D7B673A7-21C3-459D-B6F8-87154F3B028CQ27702922-A96171F2-0C42-4582-9BB0-C9EAD59E6495Q27853157-708FDC9C-125E-4822-8553-4286E413E185Q27853164-1DE6A374-F141-4DB6-B39D-627C80FFAD73Q28073283-FF8F165E-4FBD-4817-B3D0-ECE0C088AA04Q28076097-4F7F764B-878E-4348-80D4-77E55C8BADC0Q28481370-6731224D-03CE-427A-91F5-F6C7446DA13BQ28483176-FEA03630-869B-40D9-9B15-1B0E0E6D6DB8Q28483300-BF77418E-D5E8-4FB7-B521-0189999FD2D9Q28487333-AFA7FE2C-254D-4BC5-B5A5-6A439CBD00E5Q28488026-ADB7E276-78BA-4BB6-B97E-BA7935E873FFQ28537857-F674F64D-00F8-4221-9C70-B0E4DE91C91FQ28541231-91D1769D-4E09-46E9-9527-9FBCF8060517Q28547069-78D42386-A65C-4CA8-A01D-C7904C8601BBQ28551145-A41F6EB9-0B02-44A8-9465-B82BBA6F3BD3Q28598343-347170C6-CC67-4583-858B-B08A34990DEAQ28641649-AF186753-4389-43BC-986E-04CD08CCD7CEQ30384542-BF16CCE8-1180-422D-A8B5-ADEF992A043EQ30430515-72E85E19-E9CC-4469-9E5D-5C1579334960Q30446943-0585A21E-F3B4-4538-808C-67A4E117E4A2Q30464008-50F376E3-8F9A-4FDA-8274-1441EB1D4904Q30505415-7B5666B2-4FCF-4587-A488-4D78D4D8A961Q30531713-932BD4C6-13F8-492B-8B2C-E02CEA918025Q30538234-68AFBE45-45BA-486F-801A-215859D6DFB8Q30580509-C17BAA9A-F26A-4396-B2DA-35082A481DE7Q30660258-F3B926E4-186E-423B-B02A-0005C24AB6ABQ30867387-ABFFDA62-94EA-4287-AE3B-F13450EBFBDFQ33555207-637B834D-F7BF-4AAE-A152-CEEC2A6A6DABQ33576802-76706F5F-278C-4A49-B53B-B21874F823DFQ33619259-45372727-EFB9-45CD-8E45-431238FEF80AQ33637214-EAEED769-5E45-4765-A9E1-57CDBE88BF7BQ33676812-183A408C-2271-4025-9F93-FAF5177DC6A7
P2860
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cell line-based platforms to e ...... f candidate anticancer agents.
@en
Cell line-based platforms to e ...... f candidate anticancer agents.
@nl
type
label
Cell line-based platforms to e ...... f candidate anticancer agents.
@en
Cell line-based platforms to e ...... f candidate anticancer agents.
@nl
prefLabel
Cell line-based platforms to e ...... f candidate anticancer agents.
@en
Cell line-based platforms to e ...... f candidate anticancer agents.
@nl
P2093
P2860
P356
P1476
Cell line-based platforms to e ...... f candidate anticancer agents.
@en
P2093
Daniel A Haber
Jeff Settleman
Sreenath V Sharma
P2860
P2888
P304
P356
10.1038/NRC2820
P407
P577
2010-03-19T00:00:00Z
P5875
P6179
1012705094